Sympathetic ophthalmia

disease
On this page

Also known as sympathetic uveitis

Summary

Sympathetic ophthalmia (MONDO:0019198) is a disease. A subtype of panuveitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: <1 / 1 000 000 (United Kingdom) [Orphanet-validated]
  • Phenotypes (HPO): 26

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Annual incidence<1 / 1 000 0000.03United KingdomValidated
Point prevalence1-9 / 1 000 0000.6EuropeNot yet validated

Signs & symptoms

Clinical features (HPO)

26 HPO clinical features (Orphanet curated; top 26 by frequency):

HPO IDTermFrequency
HP:0007663Reduced visual acuityVery frequent (80-99%)
HP:0000501GlaucomaFrequent (30-79%)
HP:0000518CataractFrequent (30-79%)
HP:0000541Retinal detachmentFrequent (30-79%)
HP:0011531VitritisFrequent (30-79%)
HP:0025341Corneal keratic precipitatesFrequent (30-79%)
HP:0025560Anterior chamber cellsFrequent (30-79%)
HP:0030823Scleral thickeningFrequent (30-79%)
HP:0000360TinnitusOccasional (5-29%)
HP:0000365Hearing impairmentOccasional (5-29%)
HP:0000573Retinal hemorrhageOccasional (5-29%)
HP:0000613PhotophobiaOccasional (5-29%)
HP:0001045VitiligoOccasional (5-29%)
HP:0001085PapilledemaOccasional (5-29%)
HP:0001596AlopeciaOccasional (5-29%)
HP:0002290PoliosisOccasional (5-29%)
HP:0002315HeadacheOccasional (5-29%)
HP:0007680Depigmented fundusOccasional (5-29%)
HP:0007906Ocular hypertensionOccasional (5-29%)
HP:0010783ErythemaOccasional (5-29%)
HP:0011484Posterior synechiae of the anterior chamberOccasional (5-29%)
HP:0012123Posterior uveitisOccasional (5-29%)
HP:0040049Macular edemaOccasional (5-29%)
HP:0100832Vitreous floatersOccasional (5-29%)
HP:0200026Ocular painOccasional (5-29%)
HP:6000710Dalen Fuchs nodulesOccasional (5-29%)

Identifiers

Disease identifiers

FieldValue
Canonical namesympathetic ophthalmia
Mondo IDMONDO:0019198
EFOEFO:1001205
MeSHD009879
Orphanet79098
DOIDDOID:12029
ICD-10-CMH44.13
ICD-111639718137
SNOMED CT75315001
UMLSC0029077
MedGen45203
GARD0018939
MedDRA10042742
Is cancer (heuristic)no

Also known as: sympathetic ophthalmia · sympathetic uveitis

Disease family

This is a subtype of panuveitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital regioneye disorderuveal disorderuveitispanuveitissympathetic ophthalmia

Related subtypes (3): infectious panuveitis, idiopathic panuveitis, Vogt-Koyanagi-Harada disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

4 approved drugs — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugStatus
Cortisone AcetateApproved (phase 4)
DexamethasoneApproved (phase 4)
PrednisoloneApproved (phase 4)
PrednisoneApproved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.